

## **Antibacterial activity of *Candida albicans* aspartyl proteinase**

Azhar A. Ibrahim\* Ph.D  
Rassool Dabbagh\*\* Ph.D

### **Summary:**

*J Fac Med Baghdad*  
2005; Vol. 47, No.3  
Received Dec.2003  
Accepted Feb.2004

**Background:** *Candida* species are present as normal body flora on the skin, buccal cavity, vagina and intestinal tract of many individuals. Low molecular weight protein produced by many intestinal microflora, inhibits the growth of *Candida* species, while broad-spectrum antibiotics kill most of these microflora, in turn *Candida* becomes activated and overgrow.

**Aim:** to study the effect of *Candida* proteinase on some Gram-negative & Gram-positive bacteria.

**Material & methods:** Pour plate method used to incorporate the tested bacteria in nutrient agar medium. Wells were punched with sterile cork porer. 40 of different concentrations of the enzyme was placed in each well. Zones of inhibition were measured after 24 hrs of incubation at 37°C.

**Results:** Concentrations of 40:1 and 20:20 were inhibitory for *Klebsiella*, *E.coli* and *Enterobacter*; While dilutions of less than 50% of the enzyme were not effective against these bacteria, with the exception to lactobacilli.

**Key words:** Antibacteria, *C.albicans* Proteinase.

### **Introduction**

*Candida* species are present as normal body flora on the skin, buccal cavity, vagina and intestinal tract of many individuals (Rippon, 1988)<sup>(1)</sup>. Iraqi populations carry *Candida* species in intestinal tract in a high percentage reaches up to 54% (Dabbagh, 1979)<sup>(2)</sup>. One of the problems we have encountered in individuals receiving broad-spectrum antibiotics as ampicillin, is overgrowth of *Candida* species in the intestine. Such persons may develop abdominal cramps, gases and other symptoms, which may lead to diarrhea. Low molecular weight protein produced by many intestinal microflora, inhibits the growth of *Candida* species (Mahdi et al. 1993)<sup>(3)</sup>. Such broad-spectrum antibiotics kill most of these microflora, in turn *Candida* becomes activated and overgrow.

Aspartyl proteinase is considered to be one of the important factors produced by *Candida albicans* to play a major role in its virulence (De Bernard's et al. 1995)<sup>(4)</sup>. The ecological relationship between *Candida* and intestinal microflora is one of the deciding factors for allowing *Candida* to be present in sufficient number, so that under such conditions *Candida albicans* may arise (Mahdi et al. 1993)<sup>(5)</sup> In this work we noticed great effect of *C.albicans* proteinase on some Gram-negative and Gram-positive bacteria.

### **MATERIALS AND METEHODS:**

*Candida albicans* used in this work was isolated from a leukaemic patient. The organism showed typical characteristics of *C.albicans* by conventional methods (Emmons et al. 1970)<sup>(6)</sup>.

Aspartyl proteinase was prepared from *Candida albicans* according to Odds (1988)<sup>(7)</sup>. Antibacterial activity of *C.albicans* proteinase enzyme was determined against each of *E.coli*, *Klebsiella* spp., *Enterobacter* spp., *Ps. aeruginosa* and lactobacilli isolated from different clinical specimens of patients admitted to the teaching hospital of Kadhimya. These bacteria were identified by conventional methods according to Cruickshank (1975)<sup>(8)</sup>

Petri dishes were poured with two layers of nutrient agar, the upper layer of the agar medium was inoculated with one of the above mentioned bacteria from actively growing 24 hrs cultures of a concentration of 1% (bacteria/medium) (Cruickshank et al. 1975)<sup>(9)</sup>. The inoculated medium was left to dry, then punched with sterile cork porer. Different concentrations of proteinase were used. A 40 [i] of the enzyme was placed in each well. Inoculated media were incubated at 37°C for 18-24 hrs. Zones of inhibition were measured for each concentration used.

### **RESULTS:**

Table 1 shows the activity of *C.albicans* proteinase enzyme on a group of Gram-negative bacteria namely *E.coli*, *Klebsiella* spp and *Enterobacter* spp. Concentrations of the enzyme 40:1 and 20:20 were active and gave zones of inhibition ranging from 8-15

\*Iraqi Med. College Dept. of Microbiology, Nahrin Univ.  
\*\*Dept. of Microb. Med, College, Baghdad Univ.

mm in diameter; While dilution less than 50% didn't have any effect on the bacteria.

On the other hand the enzyme has no activity on *Pseudomonas aeruginosa*. Among the Gram-positive bacteria used in this contest was *Lactobacilli*. Table 2 shows activity of the enzyme against this bacteria. It is of interest to notice that the enzyme was active against *Lactobacilli* even in concentration less 50%.

Table 1- Antibacterial activity of *C.albicans* proteinase against different Gram-negative bacteria.

Type of bacteria	Dilution	Inhibition zone (mm)	Activity of enzyme (unit)
<i>E. coli</i>	0 (Control: dist. Water)	0	0
	40: 1		7.28
	30:10 20:20		5.46 3.64
<i>Klebsiella spp.</i>	0 (control: Dist. Water)	0	0
	40: 1	17	7.28
	20:20	12	3.64
	15:25	0	2.73
<i>Enterobacter spp.</i>	0 (Control: dist. Water)	0	0
	40: 1	15	7.28
	20:20	8.0	3.64
	15:25		2.73

Table-2: Antibacterial activity of *C.albicans* proteinase against *Lactobacilli*.

Type of bacteria	Dilution	Inhibition zone Mm	Activity of enzyme(unit)
<i>Lactobacilli</i>	0 (Control: dist.water)	0	0
	40: 1	15	7.28
	20:20	9.0	3.64
	15:25	6.00	2.73
	10:30		1.82

## DISCUSSION

One of the attracting phenomenon observed is antibacterial activity of aspartyl proteinase of *Candida albicans*. Some of the intestinal microflora were tested in this respect. Among the organisms tested were *E.coli*, *Klebsiella spp.*, *Enterobacter spp.*, and *Pseudomonas spp.* *E.coli* was inhibited by proteinase in concentration of

7.28 and 5.46 units. The inhibition zones were 10 and 8 mm in diameter. *Enterobacter spp.* was inhibited by proteinase enzyme in concentrations of 7.28 and 3.64 units showing zones of inhibition of 15.0 and 8.0 mm in diameter. On the same token *Klebsiella spp.* and *lactobacilli* showed sensitivity toward aspartyl proteinase of *C.albicans* as shown in table 1 and 2.

Intestinal candidiasis often follows administration of broad spectrum antibiotics orally or even systemically. These antibiotics usually kill most of the intestinal flora. It is well documented that many of these bacteria produce low molecular weight protein (L-protein) which has anticandidal activity (Mahdi et al. 1993)<sup>(3)</sup>. Removal of most of these bacteria allows *Candida* to overgrow and flourish (Mahdi et al. 1993)<sup>(5)</sup>. and (Hummel et al 1973)<sup>(10)</sup>. Aspartyl proteinase of *C.albicans* activity against *E.coli*, *Klebsiella* and others to be reported for the first time to the best of our knowledge.

Such activity of this enzyme may contribute in continuation of candidal intestinal infection, in a sense it inhibits growth of these microflora and may prevent their colonization in the intestine or delay their reestablishment for some time. These in turn create a situation of absence of L-protein or its presence in enough concentration to inhibit flourish of *Candida*.

## REFERENCES:

- Rippon JW. *Medical Mycology*, 3<sup>rd</sup> ed. Philadelphia: W.B. Saunders; 1988, pp: 534.
- Dabbagh R. *Candida species inhabiting the intestine of healthy individuals and patients with G.I tract disturbance*. *J Fac Med (Baghdad)* 1979; 21: 74-78.
- Mahdi LK and Dabbagh R. *Candidal inhibitor produced by some intestinal flora*. *J Comm Med* 1993; 6: 217-227.
- De Bernard's F, Cassone A, Sturternt J and Calderone RA. *Expression of C.albicans Sap 1 and Sap 2. In experimental vaginitis*. *Infect and Immunity* 1995; 63: 1887-1891.
- Mahdi LK and Dabbagh R. *Candida species as intestinal flora, their overgrowth and absence*. M.sc thesis. Baghdad University, 1993.
- Emmons CW, Binford CH and Uptz JP. *Medical Mycology*. 3<sup>rd</sup> ed. New York, London: Churchill Livingstone; 1970, pp: 18.
- Odds FC. *Candida and Candidiasis*. 2<sup>nd</sup> ed. Bailliere Tindal; 1988, pp: 1-3.
- Cruickshank R. *Medical Microbiology*. 12<sup>th</sup> ed. N.Y., London: Churchill Livingstone; 1975, vol. I, pp: 151 - 159.
- Cruickshank R, Dugoid JP, Marmion BP and Swain RH. *Medical Microbiology*. 12<sup>th</sup> ed. Edinburgh: Churchill Livingstone; 1975, vol. II, pp: 306.
- Hummel RP, Ostreicher EJ, Mefey MP, and Memilan BG. *Inhibition of Candida by E.coli*. *J Surgical Research* 5: 1973; 15: 53-58.